You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中生製藥(01177.HK)彈逾13% 即將有重磅對外授權落地
阿思達克 06-12 10:11
中生製藥(01177.HK)今日(12日)高開4.82%後升幅擴大,最高見5.58元。現報5.41元,升13.42%,成交2.54億股,涉資13.6億元。 中生製藥資本市場負責人雷鳴表示,對外授權已成為公司重要戰略目標之一,近期將有一筆標誌性的重磅對外授權交易落地。今年開始,商業拓展(BD)交易將成為公司的經常性收入及利潤來源,不僅將進一步提升公司的國際化收入佔比,開啟業績第二增長曲線,有望成為帶動公司估值重估的催化劑。 他稱,創新產品收入佔比已從2018年的16%提升至2024年的42%,預計今年將突破50%。未來三年,公司計劃每年上市至少5款創新產品,2027年創新產品收入佔比將進一步提升至60%,這個增長動力主要受惠於公司的「自研+BD」雙輪推動。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account